Similar articles

• Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.

  Akkerhuis KM, Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, Baardman T, Nehmiz G, Roth U, Klootwijk AP, Deckers JW, Simoons ML; Fibrinogen Receptor Occupancy Study (FROST) Investigators. Akkerhuis KM, et al. Eur Heart J. 2000 Dec;21(24):2042-55. doi: 10.1053/euhj.2000.2309. Eur Heart J. 2000. PMID: 11102255 Clinical Trial.
• Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines.

  Antman EM. Antman EM. Am Heart J. 2003 Oct;146(4 Suppl):S18-22. doi: 10.1016/j.ahj.2003.09.001. Am Heart J. 2003. PMID: 14564302 Review.
• Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).

  Huynh T, Theroux P, Snapinn S, Wan Y; Montreal General Hospital, Montreal, Quebec, Canada. thao.huynh@muhc.mcgill.ca. Huynh T, et al. Am Heart J. 2003 Oct;146(4):668-73. doi: 10.1016/S0002-8703(03)00255-2. Am Heart J. 2003. PMID: 14564321 Clinical Trial.
• The use of glycoprotein IIb/IIIa receptor inhibitors in unstable angina.

  Ageno W, Turpie AG. Ageno W, et al. G Ital Cardiol. 1999 Nov;29(11):1357-65. G Ital Cardiol. 1999. PMID: 10609142 Review. No abstract available.
• Antiplatelet agents in ischemic heart disease.

  May CH, Lincoff AM. May CH, et al. Handb Exp Pharmacol. 2012;(210):495-518. doi: 10.1007/978-3-642-29423-5_20. Handb Exp Pharmacol. 2012. PMID: 22918744 Review. No abstract available.